Ge Long Hui·2025-12-30 11:37Core Viewpoint - Fosun Pharma has initiated Phase I clinical trials for its integrated diagnostic and therapeutic nuclear medicine project SRT-007 in mainland China, targeting PSMA-positive metastatic castration-resistant prostate cancer [1] Group 1: Project Details - The SRT-007 project includes two injectable radioactive drugs: Gallium [68Ga] PSMA-0057 for diagnosis and Lutetium [177Lu] PSMA-0057 for treatment [1] - The total R&D investment for SRT-007 is approximately RMB 32.19 million (unaudited), including licensing fees, expected to be accumulated by November 2025 [1] Group 2: Market Context - As of the announcement date, the only approved radioactive drug targeting the same site globally is Pluvicto by Novartis AG, which is projected to generate global sales of USD 1.392 billion in 2024 [1]